Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Zhejiang Jianfeng Pharmaceutical Co., Ltd. was established on December 31, 1998. It is a wholly-owned subsidiary of Zhejiang Jianfeng Group Co., Ltd. (Stock Code: 600668). The company carries out the enterprise mission of "science and technology to create health", and focuses on the fields of chemical raw materials, Chinese and western medicine preparations, natural plant extracts and Chinese patent medicine with the development vision of "establishing peak ambition and pursuing excellent quality; making high-quality medicine for the benefit of human society. The company has a registered capital of 0.298 billion yuan and more than 1000 employees.
The company is a key high-tech enterprise of the National Torch Plan, with Zhejiang Enterprise Technology Center, Zhejiang Academician Expert Workstation, and National Postdoctoral Workstation. Ranked 64th among the top 100 Chinese pharmaceutical enterprises in 2009 and 74th among the top 100 Chinese pharmaceutical enterprises in 2018. The company has been awarded a series of honors such as national key high-tech enterprises, national intellectual property demonstration enterprises, innovative small and medium-sized enterprises in Zhejiang Province, patent demonstration enterprises in Zhejiang Province, and AAA enterprises in Zhejiang Province, such as "abiding by contracts and honoring credit". The "peak" trademark is recognized as a well-known trademark in China. The company's products are unique, adhere to the integrated business model of raw materials and preparations, and its main business is the development, production and sales of chemical raw materials and preparations. Product development closely around the five major treatment areas (cardiovascular, ophthalmology, psychiatry, pediatrics and oncology) to build product groups, service groups.
The company has established long-term cooperative relations with more than 20 famous domestic research institutes (schools), such as Shanghai Pharmaceutical Industry Research Institute of Chinese Academy of Sciences, China Pharmaceutical University, Zhejiang University, etc., to recruit senior scientific research talents, and gradually integrate with international new drug development. The company initially formed a foreign high-end research and development institutions as the source, to Shanghai and Jinhua two research centers for the digestion and reception, to Jinhua, Anhui, Tianjin base for the implementation of the technical architecture system.
The company's Sino-German joint venture Zhejiang Erying Pharmaceutical Co., Ltd., Shanghai Beika Pharmaceutical Technology Co., Ltd., Tianjin Jianfeng Natural Products Research and Development Co., Ltd., etc. are wholly-owned, holding and participating in 5 pharmaceutical manufacturing enterprises, 3 pharmaceutical trading enterprises, and national postdoctoral There are 2 scientific research workstations and 2 provincial academician expert workstations. It has three core manufacturing platforms: Anhui Dongji API production area, Zhejiang Jinhua preparation production area, and Tianjin Binhai plant extract production area.
The company has achieved high-quality development with projects and funds as the link. The company cooperated with German research institutions and was established, specializing in the R & D, production and operation of infant drugs; holding Shanghai Beika Pharmaceutical Technology Co., Ltd., specializing in the R & D, production and operation of pharmaceutical and chemical intermediates and pharmaceutical APIs, and expanding high-end pharmaceutical APIs And the international market of intermediates; the international first-class and domestic leading international production line of pharmaceutical preparations has been completed and put into production, and is about to enter the international market. The company will adhere to scientific and technological innovation, take technology and products as the carrier, promote the integration of production, teaching and research, constantly improve the company's management level and brand influence, and take the road of international development. Jianfeng Pharmaceutical advocates real culture, multi-win culture and innovative culture, adhering to the core values of "pragmatic and enterprising, steady behavior, innovation and drive; standardized management, strong execution, standardized development. The company adheres to the strategic concept of achieving multi-win in terms of customers, enterprises, employees, society, etc., and advocates the value concept that personal value is reflected in the process of realizing corporate value and social value. In the future development process, the company will continue to improve the management level of the company, continue to develop high-tech products, play a scale effect, promote the high-quality development of the company, and contribute to the cause of human health.
Sincerity and fraternity
Solidarity and mutual assistance